XIAOHONG JIANG: Open Payments
NPI 1063137263 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,307 in 34 payments from 13 companies in 2025. Trend: 2023 $633 · 2024 $1,577 · 2025 $1,307
Food & beverage: $908Long term medical supply or device loan: $399
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $451 |
| Daiichi Sankyo Inc. | 10 | $289 |
| AstraZeneca Pharmaceuticals LP | 3 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Janssen Biotech, Inc. | 2 | $76 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Caris MPI, Inc. | 2 | $37 |
| Exelixis Inc. | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
Products named: KISQALI, Enhertu, CALQUENCE, FRUZAQLA, Vanflyta, SCEMBLIX, OPDIVO, TECVAYLI.
Industry payments across MD — which companies pay providers there.
